Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Opthea completes enrolment in trial of OPT-302 for wet AMD

The Phase IIb trial is evaluating OPT-302 to treat early age-related macular degeneration. Credit: David Yorston.



  • Opthea

Go Top